FY2025 EPS Estimates for DRUG Lowered by Cantor Fitzgerald

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for shares of Bright Minds Biosciences in a research note issued on Thursday, March 13th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings of ($0.87) per share for the year, down from their previous estimate of ($0.62). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.24) per share.

Bright Minds Biosciences (NASDAQ:DRUG) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.24.

A number of other research analysts also recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $85.00 price target on shares of Bright Minds Biosciences in a report on Wednesday, February 19th. Robert W. Baird started coverage on Bright Minds Biosciences in a research report on Monday, November 25th. They set an “outperform” rating and a $75.00 price objective for the company. Baird R W upgraded Bright Minds Biosciences to a “strong-buy” rating in a report on Monday, November 25th. Finally, Piper Sandler assumed coverage on shares of Bright Minds Biosciences in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $93.00 price target for the company. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Bright Minds Biosciences presently has an average rating of “Buy” and a consensus price target of $84.33.

Bright Minds Biosciences Stock Performance

NASDAQ DRUG opened at $35.78 on Monday. The firm’s 50 day moving average price is $36.86 and its two-hundred day moving average price is $30.40. Bright Minds Biosciences has a twelve month low of $0.93 and a twelve month high of $79.02. The stock has a market cap of $252.03 million, a price-to-earnings ratio of -210.46 and a beta of -6.45.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE bought a new position in shares of Bright Minds Biosciences during the 4th quarter worth about $173,000. Jane Street Group LLC acquired a new position in Bright Minds Biosciences in the fourth quarter worth about $238,000. Atika Capital Management LLC bought a new position in Bright Minds Biosciences during the fourth quarter worth about $540,000. Millennium Management LLC acquired a new stake in Bright Minds Biosciences during the fourth quarter valued at approximately $1,454,000. Finally, Boothbay Fund Management LLC acquired a new stake in Bright Minds Biosciences during the fourth quarter valued at approximately $1,606,000. 40.52% of the stock is owned by institutional investors.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.